Get the Stockscreener App
1.98
4.81%
-0.10
After Hours:
1.93
-0.05
-2.53%
Annovis Bio Inc stock is traded at $1.98, with a volume of 277.03K.
It is down -4.81% in the last 24 hours and up +31.13% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$2.08
Open:
$2.03
24h Volume:
277.03K
Relative Volume:
0.74
Market Cap:
$38.59M
Revenue:
-
Net Income/Loss:
$-40.94M
P/E Ratio:
-0.5156
EPS:
-3.84
Net Cash Flow:
$-22.97M
1W Performance:
+10.61%
1M Performance:
+31.13%
6M Performance:
-70.23%
1Y Performance:
-72.03%
1-Day Range:
$1.945
$2.0599
1-Week Range:
$1.7318
$2.20
52-Week Range:
$1.11
$17.88
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.98 | 34.88M | 0 | -40.94M | -22.97M | -3.84 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MyChesCo
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus
Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus
Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -
Annovis Bio Appoints New Principal Financial Officer - TipRanks
Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com
Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - GlobeNewswire
Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN
Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -
Annovis Bio hires new director of biostatistics amid AD trial - Investing.com
Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com
Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan
LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Head-To-Head Survey: Eterna Therapeutics (NASDAQ:ERNA) and Annovis Bio (NYSE:ANVS) - Defense World
Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada
Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com
Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Buntanetap for Parkinson’s disease - Parkinson's News Today
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India
Annovis Bio Receives Non-Compliance Notice from NYSE - MSN
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN
Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa
Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener
Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks
Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire
NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire
Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):